stocksbrew

Why Sellas Life Sciences Group Inc. (SLS) Stock Rose 156.4% on Nov 17, 2026

as of Tuesday, 4:25 PM ET

The reason we found

SELLAS surges after leukemia vaccine succeeds in Phase 3 trial

SELLAS reported that its galinpepimut-S cancer vaccine met the primary endpoint in the Phase 3 REGAL trial, reducing the risk of death by 41% and extending median survival. The positive late-stage result materially improves the therapy’s commercial prospects, plausibly driving the stock’s 156.76% jump.

clinical trial resulthigh confidence

Sources 10

Weekend

Still Sunday. Nothing's moving except the clock.

1days01hrs24min47sec

Market opens Monday, Nov 23 at 9:30 AM ET